Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT — Stella

Home/Hepatocellular Carcinoma Non-resectable/

View on ClinicalTrials.gov

Recruiting

Back to Hepatocellular Carcinoma Non-resectable trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Collaborators

Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China

Enrollment target

~320 participants

Started

April 2025

Primary completion

March 2029

Age range

18 Years – 75 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.